Rhumbline Advisers grew its holdings in Becton, Dickinson and Company (NYSE:BDX) by 2.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 357,773 shares of the medical instruments supplier’s stock after purchasing an additional 9,811 shares during the period. Rhumbline Advisers owned approximately 0.16% of Becton, Dickinson and worth $70,106,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the stock. Guardian Life Insurance Co. of America grew its position in Becton, Dickinson and by 0.7% during the 1st quarter. Guardian Life Insurance Co. of America now owns 819 shares of the medical instruments supplier’s stock worth $150,000 after acquiring an additional 6 shares during the last quarter. Family Firm Inc. lifted its stake in shares of Becton, Dickinson and by 0.5% in the 2nd quarter. Family Firm Inc. now owns 1,212 shares of the medical instruments supplier’s stock valued at $236,000 after purchasing an additional 6 shares during the period. Northwest Quadrant Wealth Management LLC lifted its stake in shares of Becton, Dickinson and by 0.4% in the 2nd quarter. Northwest Quadrant Wealth Management LLC now owns 1,686 shares of the medical instruments supplier’s stock valued at $332,000 after purchasing an additional 6 shares during the period. Wellington Shields & Co. LLC lifted its stake in shares of Becton, Dickinson and by 0.3% in the 2nd quarter. Wellington Shields & Co. LLC now owns 2,541 shares of the medical instruments supplier’s stock valued at $496,000 after purchasing an additional 7 shares during the period. Finally, Northstar Group Inc. lifted its stake in shares of Becton, Dickinson and by 0.3% in the 2nd quarter. Northstar Group Inc. now owns 2,994 shares of the medical instruments supplier’s stock valued at $584,000 after purchasing an additional 9 shares during the period. Institutional investors and hedge funds own 86.01% of the company’s stock.

In other Becton, Dickinson and news, EVP Linda M. Tharby sold 4,695 shares of the business’s stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $200.48, for a total transaction of $941,253.60. Following the completion of the sale, the executive vice president now directly owns 18,670 shares of the company’s stock, valued at approximately $3,742,961.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Gary M. Cohen sold 15,512 shares of the business’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $203.77, for a total value of $3,160,880.24. Following the sale, the insider now directly owns 95,781 shares of the company’s stock, valued at $19,517,294.37. The disclosure for this sale can be found here. Insiders have sold a total of 47,038 shares of company stock valued at $9,480,225 over the last three months. Corporate insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company (BDX) traded down $1.36 during mid-day trading on Thursday, reaching $219.10. The company had a trading volume of 811,500 shares, compared to its average volume of 1,329,950. Becton, Dickinson and Company has a fifty-two week low of $161.29 and a fifty-two week high of $225.23. The company has a current ratio of 5.56, a quick ratio of 5.01 and a debt-to-equity ratio of 1.48. The firm has a market cap of $50,168.98, a P/E ratio of 23.23, a P/E/G ratio of 1.73 and a beta of 1.04.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, topping analysts’ consensus estimates of $2.37 by $0.03. The firm had revenue of $3.17 billion during the quarter, compared to analyst estimates of $3.14 billion. Becton, Dickinson and had a return on equity of 22.51% and a net margin of 8.52%. The company’s revenue for the quarter was down 2.0% on a year-over-year basis. During the same period in the previous year, the company posted $2.12 EPS. equities analysts predict that Becton, Dickinson and Company will post 10.63 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/11/16/becton-dickinson-and-company-bdx-stake-boosted-by-rhumbline-advisers.html.

A number of brokerages have recently issued reports on BDX. Barclays PLC reissued an “equal weight” rating and issued a $210.00 price objective (up from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. BidaskClub downgraded Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Zacks Investment Research raised Becton, Dickinson and from a “sell” rating to a “hold” rating in a research note on Friday, October 20th. Stifel Nicolaus reissued a “buy” rating on shares of Becton, Dickinson and in a research note on Wednesday, August 9th. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $213.00 price objective on shares of Becton, Dickinson and in a research note on Tuesday, September 12th. Five equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $213.47.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.